Motilin
Navigation Links
Motilin in Medical News
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
... addition to its lead programs in Hsp90 inhibition and epothilones, Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is progressing in a Phase 1 trial as... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustai...Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results
...ar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GER...Motilin in Medical Technology
HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that Pfizer Inc. has initiated
a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly
KOS-2187, a selective and potent motilin receptor agonist being developed
...
... epothilone products in order for Kosan to receive milestones or royalties, Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...
...1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety tria... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustai...
... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GER...
... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...
... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...
... epothilone products in order for Kosan to receive milestones or royalties, Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'......1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety tria... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustai...
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
...r to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD). Thi...... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GER...
... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...
... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...
Motilin in Biological Technology
Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
Vronique Brechler, David Handfield, Martin Boissonneault, Esther Tremblay, Benoit Houle and Luc Mnard. Introduction Recent advances in combinatorial chemistry and genomics programs have led to an unprecedented increase in both the number of compounds and potential...Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
... one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on...Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
... one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on...Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
...ty to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer
...ty to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan......lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan...
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
...k and time to commercialization. -- Kosan's motilin agonist KOS-2187 has been licensed to Pfizer and i...ical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is...s collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additi...Motilin in Biological Definition
...Y)
Opioids :
corticotropin (ACTH)
Beta-lipotropin
dynorphin
endorphin
enkephaline
leumorphin
Secretins:
secretin
motilin
glucagon
vasoactive intestinal peptide (VIP)
growth hormone-releasing factor (GRF)
Somatostatins:
somatostatin
Tachykinins :...
Other TagsStorStorStorStorStorCompCompCompCompCompCompCompCompSenaSenaMallMallMallMallMallMallOther Contentsepiglottitisenteromanometryenuresiseosinophilepicondylitisepidemicepidemicepidemicepidemicepidemicepidemic
(Date:12/3/2009)... 3 The following is bei..., U.S. Senate Judiciary Committee Chairman Patr...health care reform bill that would repeal the heal...tions such as price fixing, bid rigging and market...es the repeal, which would subject health insuranc...
(Date:12/3/2009)...n 1,500 Jobs Listed through APHA,s Public Health C...-USNewswire/ -- Today,s White House jobs summit re...ny professions, including public health. One publi...ect job seekers to more than 1,500 jobs in the hea...://www.apha.org/about/careers/ is a full online c...
(Date:12/3/2009)...ches rzteblatt International contains the first s...h the novel influenza A virus (H1N1/09) in the Ger...emic. Ralf Winzer and his coauthors from the Dssel... data from a large clinical cohort of infected per...: 770-6). Their medical-scientific article is acco...
(Date:12/3/2009)...atori World Medical, a leading global healthcare c... space, announced that international medical quali...Medical Quality Advisory Board (MQAB). , ...2009 –- Satori World Medical, a leading glob... medical travel space, announced that internationa...
(Date:12/3/2009)...wed, the more likely they were to light up, study ...ws) -- Seeing movie characters smoke cigarettes in...try smoking, according to a new study that calls f...ng. , It followed 1,328 Mexican-American adoles... types of movies they viewed. , At the start of...
Breaking Medicine News(10 mins):Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 3Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 4Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 5Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 6Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 7Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 8Health News:Public Health Jobs Site Available to Help Meet Growing Demand 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Movies May Tempt Teens to Smoke 2[0] Health Insurance Industry Once Again Hoping Investment Pays Off[0] Public Health Jobs Site Available to Help Meet Growing Demand[0] The swine flu pandemic[0] Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board[0] Movies May Tempt Teens to Smoke
(Date:12/2/2009)...g adults who are fit have a higher IQ and are more...w study carried out at the Sahlgrenska Academy and...were published today in the prestigious Proceedin...The study involved 1.2 million Swedish men doing m...6. The research group analysed the results of both...
(Date:12/2/2009)...ientists are reporting the first identification of...ormation that changes harmless marine bacteria int...y appears in ACS, Environmental Science & Technol...colleagues note that bleaching already has destroy...d scientists are searching for ways to slow or sto...
(Date:12/2/2009)...ngle-walled nanotubescylinders of carbon about a n...tential applications such as ultrastrong fibers, e...storage components for fuel cells. Thanks to a new...ute of Standards and Technology (NIST) and five pa...st: detection and destruction of an aggressive for...
Breaking Biology News(10 mins):Young adults who exercise get higher IQ 2Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Akorn Inc Announces Third Quarter 2009 Earnings Release and Conference Call Information 60113 1Solutia Reports Third Quarter 2009 Results 14597 1Solutia Reports Third Quarter 2009 Results 14597 2Solutia Reports Third Quarter 2009 Results 14597 3Solutia Reports Third Quarter 2009 Results 14597 4Solutia Reports Third Quarter 2009 Results 14597 5Solutia Reports Third Quarter 2009 Results 14597 6Solutia Reports Third Quarter 2009 Results 14597 7Solutia Reports Third Quarter 2009 Results 14597 8Solutia Reports Third Quarter 2009 Results 14597 9Solutia Reports Third Quarter 2009 Results 14597 10Solutia Reports Third Quarter 2009 Results 14597 11Solutia Reports Third Quarter 2009 Results 14597 12Solutia Reports Third Quarter 2009 Results 14597 13Solutia Reports Third Quarter 2009 Results 14597 14Solutia Reports Third Quarter 2009 Results 14597 15Solutia Reports Third Quarter 2009 Results 14597 16Solutia Reports Third Quarter 2009 Results 14597 17Solutia Reports Third Quarter 2009 Results 14597 18Solutia Reports Third Quarter 2009 Results 14597 19Solutia Reports Third Quarter 2009 Results 14597 20Solutia Reports Third Quarter 2009 Results 14597 21Solutia Reports Third Quarter 2009 Results 14597 22Solutia Reports Third Quarter 2009 Results 14597 23Solutia Reports Third Quarter 2009 Results 14597 24Solutia Reports Third Quarter 2009 Results 14597 25Solutia Reports Third Quarter 2009 Results 14597 26New Incision Less Procedure for REFLUX Experts Consider it to Be Gold Standard for REFLUX 5717 1New Incision Less Procedure for REFLUX Experts Consider it to Be Gold Standard for REFLUX 5717 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |